On Wednesday, the CDC's Advisory Committee on Immunization Practices concluded that the nasal spray flu vaccine should not be used for the 2016-2017 flu season.
The ACIP vote was based on data suggesting lower efficacy for the nasal spray vaccine when compared to the shot. Preliminary data on 2015-2016 flu season vaccinations on children ages 2 to 17 displayed a 63 percent rate of effectiveness for the flu shot compared to a 3 percent rate for the nasal spray.
The CDC also stated that the nasal spray vaccine appeared ineffective in the two prior flu seasons as well.
The decision could have implications for both vaccine manufactures and providers who have already ordered the FluMist Quadrivalent flu vaccine produced by MedImmune.
In a statement, the CDC said, "The ACIP recommendation may particularly affect pediatricians and other vaccine providers for children since data from recent seasons suggests nasal spray flu vaccine accounts for about one-third of all flu vaccines given to children. CDC will be working with manufacturers throughout the summer to ensure there is enough vaccine supply to meet the demand."
The committee's recommendation must be confirmed by the CDC's director before it becomes policy. Official recommendations for the use of influenza vaccines in the upcoming flu season will be published in late summer or early fall.
More articles on infection control:
Colistin-resistant E. coli is carried by seagulls, researchers suggest
100 in Florida may have been exposed to measles
Ohio teen killed by brain-eating amoeba